Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates

Edmund C. Boese, Kermit R. Tantum, M. Elaine Eyster

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Antihemophilic factor (AHF) concentrates contain debris which passes freely through the 170 μ filter routinely used for patient infusion. We have previously shown that this material is composed in part of IgG, fibrinoprotein and cold-insoluble globulin and that it is retained by a screen filter of 40 μ pore size. The purpose of this study was to investigate pulmonary effects of this particulate material in hemophiliac patients receiving frequent AHF infusions. Pulmonary function studies were performed before and after the infusion of a standard dose of AHF concentrate calculated to raise the in vivo factor VIII level to 50 per cent of normal. Using a standard 170 μ filter, five of six patients showed a significant decrease (p < 0.01) in the single breath carbon monoxide diffusing capacity (DLCOSB) 30 minutes and 6 hours after the infusion, with values returning to preinfusion levels by 48 hours. Slow vital capacity, forced vital capacity, maximum voluntary ventilation and a helium dilution residual lung volume remained normal in all patients. Two patients who were restudied using a 40 μ filter showed no significant change in the DLCOSB after the infusion. We conclude that lodging of particulate material in the pulmonary capillary bed was most likely responsible for the reduced DlCOsb. Since the defect was prevented by microfiltration, the use of a finer mesh filter than is currently recommended may be desirable for hemophiliac patients receiving large amounts of AHF concentrate at frequent intervals.

    Original languageEnglish (US)
    Pages (from-to)474-476
    Number of pages3
    JournalThe American Journal of Medicine
    Volume67
    Issue number3
    DOIs
    StatePublished - Jan 1 1979

    Fingerprint

    Lung
    Vital Capacity
    Helium
    Residual Volume
    Factor VIII
    Carbon Monoxide
    Fibronectins
    Ventilation
    human F8 protein
    Immunoglobulin G

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cite this

    @article{74ee0850808b41209fa39517def000e0,
    title = "Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates",
    abstract = "Antihemophilic factor (AHF) concentrates contain debris which passes freely through the 170 μ filter routinely used for patient infusion. We have previously shown that this material is composed in part of IgG, fibrinoprotein and cold-insoluble globulin and that it is retained by a screen filter of 40 μ pore size. The purpose of this study was to investigate pulmonary effects of this particulate material in hemophiliac patients receiving frequent AHF infusions. Pulmonary function studies were performed before and after the infusion of a standard dose of AHF concentrate calculated to raise the in vivo factor VIII level to 50 per cent of normal. Using a standard 170 μ filter, five of six patients showed a significant decrease (p < 0.01) in the single breath carbon monoxide diffusing capacity (DLCOSB) 30 minutes and 6 hours after the infusion, with values returning to preinfusion levels by 48 hours. Slow vital capacity, forced vital capacity, maximum voluntary ventilation and a helium dilution residual lung volume remained normal in all patients. Two patients who were restudied using a 40 μ filter showed no significant change in the DLCOSB after the infusion. We conclude that lodging of particulate material in the pulmonary capillary bed was most likely responsible for the reduced DlCOsb. Since the defect was prevented by microfiltration, the use of a finer mesh filter than is currently recommended may be desirable for hemophiliac patients receiving large amounts of AHF concentrate at frequent intervals.",
    author = "Boese, {Edmund C.} and Tantum, {Kermit R.} and Eyster, {M. Elaine}",
    year = "1979",
    month = "1",
    day = "1",
    doi = "10.1016/0002-9343(79)90796-4",
    language = "English (US)",
    volume = "67",
    pages = "474--476",
    journal = "American Journal of Medicine",
    issn = "0002-9343",
    publisher = "Elsevier Inc.",
    number = "3",

    }

    Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates. / Boese, Edmund C.; Tantum, Kermit R.; Eyster, M. Elaine.

    In: The American Journal of Medicine, Vol. 67, No. 3, 01.01.1979, p. 474-476.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates

    AU - Boese, Edmund C.

    AU - Tantum, Kermit R.

    AU - Eyster, M. Elaine

    PY - 1979/1/1

    Y1 - 1979/1/1

    N2 - Antihemophilic factor (AHF) concentrates contain debris which passes freely through the 170 μ filter routinely used for patient infusion. We have previously shown that this material is composed in part of IgG, fibrinoprotein and cold-insoluble globulin and that it is retained by a screen filter of 40 μ pore size. The purpose of this study was to investigate pulmonary effects of this particulate material in hemophiliac patients receiving frequent AHF infusions. Pulmonary function studies were performed before and after the infusion of a standard dose of AHF concentrate calculated to raise the in vivo factor VIII level to 50 per cent of normal. Using a standard 170 μ filter, five of six patients showed a significant decrease (p < 0.01) in the single breath carbon monoxide diffusing capacity (DLCOSB) 30 minutes and 6 hours after the infusion, with values returning to preinfusion levels by 48 hours. Slow vital capacity, forced vital capacity, maximum voluntary ventilation and a helium dilution residual lung volume remained normal in all patients. Two patients who were restudied using a 40 μ filter showed no significant change in the DLCOSB after the infusion. We conclude that lodging of particulate material in the pulmonary capillary bed was most likely responsible for the reduced DlCOsb. Since the defect was prevented by microfiltration, the use of a finer mesh filter than is currently recommended may be desirable for hemophiliac patients receiving large amounts of AHF concentrate at frequent intervals.

    AB - Antihemophilic factor (AHF) concentrates contain debris which passes freely through the 170 μ filter routinely used for patient infusion. We have previously shown that this material is composed in part of IgG, fibrinoprotein and cold-insoluble globulin and that it is retained by a screen filter of 40 μ pore size. The purpose of this study was to investigate pulmonary effects of this particulate material in hemophiliac patients receiving frequent AHF infusions. Pulmonary function studies were performed before and after the infusion of a standard dose of AHF concentrate calculated to raise the in vivo factor VIII level to 50 per cent of normal. Using a standard 170 μ filter, five of six patients showed a significant decrease (p < 0.01) in the single breath carbon monoxide diffusing capacity (DLCOSB) 30 minutes and 6 hours after the infusion, with values returning to preinfusion levels by 48 hours. Slow vital capacity, forced vital capacity, maximum voluntary ventilation and a helium dilution residual lung volume remained normal in all patients. Two patients who were restudied using a 40 μ filter showed no significant change in the DLCOSB after the infusion. We conclude that lodging of particulate material in the pulmonary capillary bed was most likely responsible for the reduced DlCOsb. Since the defect was prevented by microfiltration, the use of a finer mesh filter than is currently recommended may be desirable for hemophiliac patients receiving large amounts of AHF concentrate at frequent intervals.

    UR - http://www.scopus.com/inward/record.url?scp=0018698071&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0018698071&partnerID=8YFLogxK

    U2 - 10.1016/0002-9343(79)90796-4

    DO - 10.1016/0002-9343(79)90796-4

    M3 - Article

    C2 - 474593

    AN - SCOPUS:0018698071

    VL - 67

    SP - 474

    EP - 476

    JO - American Journal of Medicine

    JF - American Journal of Medicine

    SN - 0002-9343

    IS - 3

    ER -